What the Approval of IMAAVY Means for Patients With wAIHA @checkrare
What the Approval of IMAAVY Means for Patients With wAIHA  @checkrare
Uploaded September 2026 | Updated November 2026, 2 days ago
Karen A. Jones, EdD, President and CEO of wAIHA Warriors, discusses the approval of Imaavy (nipocalimab) and its impact on patients with warm autoimmune hemolytic anemia (wAIHA).
What the Approval of IMAAVY Means for Patients With wAIHAUltragenyx Sells PRV for $210M | The CheckRare Brief Ep 11Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team?Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPFPrimary IGF-1 DeficiencyFabry Disease: What Symptoms Should Be Better Managed By Your Medical Team?Episode 1: FDA Advisory Board’s Concerns About New Duchenne Drug, Brain Fog in Immune Thrombocyto...Diagnosing Seronegative Myasthenia GravisImportance of Patient Listening in The Development of Rare Disease TreatmentsENERGY Clinical Trial Testing Imaavy (Nipocalimab) in Warm Autoimmune Hemolytic Anemia (wAIHA)What to Expect: 2026 MGFA Scientific SessionBurdensome Symptoms in Fabry Disease
CheckRare |

What the Approval of IMAAVY Means for Patients With wAIHA

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER